At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
STA-9090drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma
In Brief
A Phase 2 clinical trial evaluating STA-9090 for Ocular Melanoma. Completed, enrolled 17 participants across 3 sites.
Detailed Summary
STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of STA-9090 efficacy to metastatic ocular melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Melanoma
CountriesUnited States
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartSep 2010
Primary CompletionOct 2014
Study CompletionNov 2016
TodayJul 2026
First PostedSep 13, 2010
Enrollment StartSep 17, 2010
Primary CompletionOct 12, 2014
Study CompletionNov 11, 2016
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 15.8 years ago
Interventions
STA-9090drug